Nose to brain delivery of selegiline loaded PLGA/lipid nanoparticles: Synthesis, characterisation and brain pharmacokinetics evaluation

Subashini Raman a, Arshad Ali Khan a,b, Syed Mahmood a,c,*

a Department of Pharmaceutical Engineering, Faculty of Chemical and Process Engineering Technology, Universiti Malaysia Pahang, Gambang, 26300, Malaysia
b The Robert M. Berne Cardiovascular Research Center, University of Virginia, Charlottesville, 22903, Virginia, USA
c Department of Pharmaceutical Technology, Faculty of Pharmacy, Universiti Malaya, 50603, Kuala Lumpur, Malaysia

ARTICLE INFO

Keywords:
Selegiline
Parkinson’s disease
Poly(lactic-co-glycolic) acid (PLGA)
Lipid-based formulation(s)
Nasal drug delivery

ABSTRACT

Parkinson’s disease (PD) is the second most common progressive neurodegenerative disease that promotes neuronal cell death. The primary treatment strategy for Parkinson’s disease involves the therapy of an MAO-B inhibitor molecule, selegiline. The present research aims to fabricate selegiline loaded polymeric (PLGA) nanoparticles (SPNPs) and selegiline loaded lipid-PLGA hybrid nanoparticles (SLPNPs) while using the single emulsion solvent evaporation method. The prepared SPNPs and SLPNPs formulations were subjected to preliminary optimisation using particle size, zeta-potential, and entrapment efficiency (EE%), and the selected formulations were subjected to further characterisation. Scanning electron microscopy (SEM) and high-resolution transmission electron microscopy (HRTEM) confirmed the particles’ 2-D spherical morphology and size. ATR-FTIR was used to evaluate the physical interactions among the formulation ingredients. Differential scanning calorimetry (DSC) and X-ray diffraction (XRD) studies confirm that SPNPs and SLPNPs were in an amorphous state. Ex-vivo studies showed 77.56% and 80% of drug permeation in 24 h for optimised formulations of SPNPs-2 and SLPNPs-1, respectively, while pure selegiline showed 65% Permeation. In-vivo study revealed a steady and controlled release profile with a half-life of 13.5 h, and AUC0-24 was observed at 130327.56 ± 231.6 ng/ml*h for SPNPs-2. For SLPNPs-1 an immediate release was observed with a very short half-life and AUC0-24 47548.57 ± 434.8 ng/ml*h compared with pure selegiline HCl solution with 2.3 h and AUC0-24 11116.52 ± 345.7 ng/ml*h. SLPNPs-1 has a shorter half-life due to its immediate release properties with the presence of lipid. Meanwhile, SPNPs-2, which only has a polymeric layer, has a longer half-life due to its sustained release properties. Overall, SPNPs-2 and SLPNPs-1 are promising carriers for selegiline nasal uptake and increase its brain bioavailability compared to oral absorption by pure selegiline.

1. Introduction

A recent report from the World Health Organization shows that over 1.5 billion people worldwide are currently affected by neurological disorders such as Alzheimer’s Disease (AD), Parkinson’s Disease (PD), stroke, headache, brain injuries, epilepsy, neuro infection, and multiple sclerosis [1, 2]. Neurodegenerative diseases are conditions that affect the functioning of neurons in the brain by fluctuations in neurological functions [3]. The neuropathological hallmarks of PD are neuronal loss in the substantia nigra, which causes striatal dopamine deficiency, and intracellular inclusions containing aggregates of α-synuclein [4]. PD comes under heterogeneous gene diseases as it follows Mendel’s law. A recent study concluded that PD is linked to α-synuclein toxicity and to lysosomal abnormalities. It indicated that idiopathic Parkinson’s disease resembles Mendelian lysosomal storage disorders at a genetic and biochemical level [4]. PD is the second most common neurodegenerative disorder, affecting 2–3% of a sexagenarian population [5].

Selegiline, an MAO-B inhibitor, was one of the first adjunct therapies in clinical neurology. It is also known as 2-propanoylephentanylethylamine. As a specific, irreversible inhibitor of MAO-B, an enzyme that catalyses dopamine metabolism in the Central Nervous System (CNS) [6]. Selegiline also plays a double role in treating PD as well as depression caused by PD. The oral daily dose approved for the management of PD is 5–10 mg. However, for parenteral and transdermal routes, some studies have found that a lower dosage (1.5 mg–5 mg) is sufficient for the same amount of efficacy, which may also benefit in reducing side effects with

* Corresponding author. Department of Pharmaceutical Technology, Faculty of Pharmacy, Universiti Malaya, 50603, Kuala Lumpur, Malaysia.
E-mail addresses: syedmahmood@um.edu.my, syed872011@yahoo.co.in (S. Mahmood).

https://doi.org/10.1016/j.jddst.2022.103923
Received 5 June 2022; Received in revised form 16 October 2022; Accepted 24 October 2022
Available online 29 October 2022
1773-2247/© 2022 Elsevier B.V. All rights reserved.